Filoviruses and the balance of innate, adaptive, and inflammatory responses

Viral Immunology

Volumn 19, Issue 4, 2006, Pages 602-612

  Mohamadzadeh, Mansour ^a,b   Chen, Lieping ^b   Olinger, Gene G ^a   Pratt, William D ^a   Schmaljohn, Alan L ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; INTERFERON; VIRUS VACCINE;

ADAPTIVE IMMUNITY; DENDRITIC CELL; EBOLA VIRUS; FILOVIRUS; HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; MARBURG VIRUS; NEUTROPHIL; NONHUMAN; REVIEW; VACCINATION; VIRUS INFECTION; VIRUS LOAD;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS;

DENDRITIC CELLS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; NEUTROPHILS; VIRAL VACCINES;

EID: 33846057827     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.602     Document Type: Review

References (86)

1. International Committee on Taxonomy of Viruses. Virus Taxonomy: Eighth Report of the International Committee on Taxonomy of Viruses. Academic Press, San Diego, CA, 2005.
2. Alibek K, and Handelman S: Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World, Told from the Inside by the Man Who Ran It, 1st ed. Random House, New York, 1999.
3. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, and Delgado R: C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002;76:6841-6844.
4. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, and Mavoungou E: Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128:163-168.
5. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Fisher-Hoch SP, McCormick JB, and Georges AJ: Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-426.
6. Baize S, Leroy EM, Mavoungou E, and Fisher-Hoch SP: Apoptosis in fatal Ebola infection: Does the virus toll the bell for immune system? Apoptosis 2000;5:5-7.
7. Banchereau J, and Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245-252.
8. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, and Ahmed R: Restoring func-tion in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
9. Baribaud F, Pohlmann S, Leslie G, Mortari F, and Doms RW: Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells. J Virol 2002;76:9135-9142.
10. Baskerville A, Bowen ET, Platt GS, McArdell LB, and Simpson DI: The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978;125:131-138.
11. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, and Garcia-Sastre A: The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003;77:7945-7956.
12. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A, and Palese P: The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000;97:12289-12294.
13. Becker S, Spiess M, and Klenk HD: The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol 1995;76:393-399.
14. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, and Tonat K: Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 2002;287:2391-2405.
15. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, and Schmaljohn A: Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188:1630-1638.
16. Bouchon A, Facchetti F, Weigand MA, and Colonna M: TREM-I amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410:1103-1107.
17. Bouchon A, Hernandez-Munain C, Cella M, and Colonna M: A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 2001;194:1111-1122.
18. Bray M: The role of the type I interferon response in the resistance of mice to Filovirus infection. J Gen Virol 2001;82:1365-1373.
19. Bray M, Raymond JL, Geisbert T, and Baker RO: 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res 2002;55:151-159.
20. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, and Sanchez A: A single intranasal inoculation with a Paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006;80:2267-2279.
21. Burnett JC, Henchal EA, Schmaljohn AL, and Bavari S: The evolving field of biodefence: Therapeutic developments and diagnostics. Nat Rev Drug Discov 2005;4:281-297.
22. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, and Van den Enden E: Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 1999;179:S1-S7.
23. Caccavo D, Pellegrino NM, Altamura M, Rigon A, Amati L, Amoroso A, and Jirillo E: Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res 2002;8:403-417.
24. Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, Saphire EO, and Basler CF: Ebola virus VP35 protein binds double-stranded RNA and inhibits α/β interferon production induced by RIG-I signaling. J Virol 2006;80:5168-5178.
25. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, and Goldsmith MA: Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 2001;106:117-126.
26. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-347.
27. Colonna M, Trinchieri G, and Liu YJ: Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-1226.
28. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, and Feldmann H: Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment. Lancet 2006;367:1399-1404.
29. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Stroher U, Klenk HD, and Volchkov V: 2004. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 2004;23:2175-2184.
30. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, and Schnittler HJ: Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996;70:2208-2214.
31. Feldmann H, Volchkov VE, Volchkova VA, and Klenk HD: The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 1999;15:159-169.
32. Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, Lloyd G, and Simpson DI: Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985;152:887-894.
33. Fowler T, Bamberg S, Moller P, Klenk HD, Meyer TF, Becker S, and Rudel T: Inhibition of Marburg virus pro-tein expression and viral release by RNA interference. J Gen Virol 2005;86:1181-1188.
34. Gear JH: Hemorrhagic fevers, with special reference to recent outbreaks in southern Africa. Rev Infect Dis 1979;1:571-591.
35. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, and Jahrling PB: Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000;80:171-186.
36. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, and Vlasuk GP: Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 2003;362:1953-1958.
37. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-Dicaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, and Maclachlan I: Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193:1650-1657.
38. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, and Davis KJ: Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347-2370.
39. Geisbert TW, and Jahrling PB: Differentiation of Filoviruses by electron microscopy. Virus Res 1995;39:129-150.
40. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, and Jahrling PB: Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8:503-507.
41. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, and Hensley LE: Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188:1618-1629.
42. Groseth A, Feldmann H, Theriault S, Mehmetoglu G, and Flick R: RNA polymerase I-driven minigenome system for Ebola viruses. J Virol 2005;79:4425-4433.
43. Hart MK: Vaccine research efforts for Filoviruses. Int J Parasitol 2003;33:583-595.
44. Hevey M, Negley D, Geisbert J, Jahrling P, and Schmaljohn A: Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997;239:206-216.
45. Hevey M, Negley D, Pushko P, Smith J, and Schmaljohn A: Marburg virus vaccines based upon Alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998;251:28-37.
46. Hevey M, Negley D, and Schmaljohn A: Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 2003;314:350-357.
47. Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, Smith JF, Jahrling PB, and Schmaljohn AL: Marburg virus vaccines: Comparing classical and new approaches. Vaccine 2001;20:586-593.
48. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, LeDuc JW, and Peters CJ: Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999;179(Suppl 1):S224-S234.
49. Johnson ED, Johnson BK, Silverstein D, Tukei P, Geisbert TW, Sanchez AN, and Jahrling PB: Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 1996;11:101-114.
50. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, and Geisbert TW: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-790.
51. Kash JC, Muhlberger E, Carter V, Grosch M, Perwitasari O, Proll SC, Thomas MJ, Weber F, Klenk HD, and Katze MG: Global suppression of the host antiviral response by Ebola- and Marburgviruses: Increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006;80:3009-3020.
52. Kim Y, Sato K, Asagiri M, Morita I, Soma K, and Takayanagi H: Contribution of nuclear factor of activated T cells cl to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005;280:32905-32913.
53. Kindzelskii AL, Yang Z, Nabel GJ, Todd RF III, and Petty HR: Ebola virus secretory glycoprotein (sGP) diminishes Fc γ RIIIB-to-CR3 proximity on neutrophils. J Immunol 2000;164:953-958.
54. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, and Mavoungou E: Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001;124:453-460.
55. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, and Swanepoel R: Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-576.
56. Liu YJ: IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
57. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, and Pulendran B: Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003;170:2797-2801.
58. Martini GA, and Siegert R: Marburg virus Disease. Springer-Verlag, Berlin, 1971.
59. Maruyama T, Buchmeier MJ, Parren PWHI, and Burton DR: Ebola virus, neutrophils, and antibody specificity. Science 1998;282:845a.
60. McVicar DW, Taylor LS, Gosselin P, Willette-Brown J, Mikhael AI, Geahlen RL, Nakamura MC, Linnemeyer P, Seaman WE, Anderson SK, Ortaldo JR, and Mason LH: DAP12-mediated signal transduction in natural killer cells: A dominant role for the Syk protein-tyrosine kinase. J Biol Chem 1998;273:32934-32942.
61. Mohamadzadeh M, Coberley SS, Olinger GG, Kalina WV, Ruthel G, Fuller CL, Swenson DL, Pratt WD, Kuhns DB, and Schmaljohn AL: Activation of triggering receptor expressed on myeloid cells-1 (TREM-1) on human neutrophils by Marburg and Ebola viruses. J Virol 2006;80:7235-7244.
62. Muhlberger E, Weik M, Volchkov VE, Klenk HD, and Becker S: Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999;73:2333-2342.
63. + T lymphocytes. J Clin Invest 2005;115:3256-3264.
64. Nathan C: Points of control in inflammation. Nature 2002;420:846-852.
65. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, and Burton DR: Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002;76:6408-6412.
66. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, and Basler CF: Ebola virus VP24 binds karyopherin α 1 and blocks STAT1 nuclear accumulation. J Virol 2006;80:5156-5167.
67. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, and Schmaljohn C: Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003;21:4071-4080.
68. Ryabchikova EI, Kolesnikova LV, and Luchko SV: An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999;179(Suppl 1):S199-S202.
69. Schmaljohn A, and Hevey M: Medical countermeasures for Filoviruses and other viral agents. In Lindler LE, Lebeda FJ, and Korch G, eds. Biological Weapons Defense: Infectious Disease Counterbioterrorism. Humana Press, Totowa, NJ, 2004. pp. 239-253.
70. Schmaljohn C, Nabel GJ, McCormick JJ, and Schmaljohn A: Vaccines for Hantaviruses, Lassa virus, and Filoviruses. In Levine MM, ed. New Generation Vaccines, 3rd ed. Marcel Dekker, New York, 2004, pp. 679-694.
71. Siegert R, Shu HL, and Slenczka W: [Isolation and identification of the "Marburg virus"]. Dtsch Med Wochenschr 1968:93:604-612.
72. Slenczka WG: The Marburg virus outbreak of 1967 and subsequent episodes. Curr Top Microbiol Immunol 1999;235:49-75.
73. Sui J, and Marasco WA: Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002;303:9-14.
74. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, and Nabel GJ: Immune protection of nonhuman primates against Ebola virus with single low-dose Adenovirus vectors encoding modified GPs. PLoS Med 2006;3:e177.
75. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, and Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-609.
76. Towner JS, Khristova ML, Sealy TK, Vincent MJ, Erickson BR, Bawiec DA, Hartman AL, Comer JA, Zaki SR, Stroher U, Gomez da Silva F, del Castillo F, Rollin P, Ksiazek TG, and Nichol ST: Marburg virus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006;80:6497-6516.
77. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, and Nichol ST: Generation of eGFP expressing recombinant Zaire Ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005;332:20-27.
78. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, Dong H, Maserati R, Shearer GM, Chen L, and Clerici M: B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003;101:2514-2520.
79. Volchkov VE, Volchkova VA, Dolnik O, Feldmann H, and Klenk HD: Polymorphism of Filovirus glycoproteins. Adv Virus Res 2005;64:359-381.
80. Volchkov VE, Volchkova VA, Stroher U, Becker S, Dolnik O, Cieplik M, Garten W, Klenk HD, and Feldmann H: Proteolytic processing of Marburg virus glycoprotein. Virology 2000;268:1-6.
81. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, and Schnittler HJ: Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005;79:10442-10450.
82. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, Yokoyama WM, Young HA, and Bavari S: Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004;200:169-179.
83. Warfield KL, Swenson DL, Demmin G, and Bavari S: Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 2005;4:429-440.
84. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, and Bavari S: Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2:e1.
85. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, and Hart MK: Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000;287:1664-1666.
86. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, and Nabel GJ: Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998;279:1034-1037.